{"pmid":32436646,"title":"Clinical outcome in solid organ transplant recipients with COVID-19: A single-center experience.","text":["Clinical outcome in solid organ transplant recipients with COVID-19: A single-center experience.","We read with great interest the report by Fernandez-Ruiz and colleagues on the outcome of 18 transplant recipients(1) with COVID-19, showing a higher case fatality rate than that reported in the general population. Unlike them, we did not observe higher mortality in transplant setting compared to our overall mortality. We collected data of 13 consecutive solid organ transplant recipients admitted to our Center for COVID-19 between February 21st and April 26th, 2020, with a median follow up of 36 days (IQR 25-41). Our patients were younger (median age 59 versus 71 years) and with a shorter median interval from transplantation (5.3 versus 9.3 years) compared to the Spanish case series. The most common comorbidities were hypertension (54%) and diabetes (31%).","Am J Transplant","Travi, Giovanna","Rossotti, Roberto","Merli, Marco","Sacco, Alice","Perricone, Giovanni","Lauterio, Andrea","Colombo, Valeriana Giuseppina","De Carlis, Luciano","Frigerio, Maria","Minetti, Enrico","Belli, Luca","Puoti, Massimo","32436646"],"abstract":["We read with great interest the report by Fernandez-Ruiz and colleagues on the outcome of 18 transplant recipients(1) with COVID-19, showing a higher case fatality rate than that reported in the general population. Unlike them, we did not observe higher mortality in transplant setting compared to our overall mortality. We collected data of 13 consecutive solid organ transplant recipients admitted to our Center for COVID-19 between February 21st and April 26th, 2020, with a median follow up of 36 days (IQR 25-41). Our patients were younger (median age 59 versus 71 years) and with a shorter median interval from transplantation (5.3 versus 9.3 years) compared to the Spanish case series. The most common comorbidities were hypertension (54%) and diabetes (31%)."],"journal":"Am J Transplant","authors":["Travi, Giovanna","Rossotti, Roberto","Merli, Marco","Sacco, Alice","Perricone, Giovanni","Lauterio, Andrea","Colombo, Valeriana Giuseppina","De Carlis, Luciano","Frigerio, Maria","Minetti, Enrico","Belli, Luca","Puoti, Massimo"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32436646","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1111/ajt.16069","locations":["Spanish"],"countries":["Spain"],"countries_codes":["ESP|Spain"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1667521393775869952,"score":9.490897,"similar":[{"pmid":32301155,"title":"COVID-19 in solid organ transplant recipients: a single-center case series from Spain.","text":["COVID-19 in solid organ transplant recipients: a single-center case series from Spain.","The clinical characteristics, management and outcome of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) after solid organ transplantation (SOT) remain unknown. We report our preliminary experience with 18 SOT (kidney [44.4%], liver [33.3%] and heart [22.2%]) recipients diagnosed with COVID-19 by March 23, 2020 at a tertiary-care center at Madrid. Median age at diagnosis was 71.0 +/- 12.8 years, and the median interval since transplantation was 9.3 years. Fever (83.3%) and radiographic abnormalities in form of unilateral or bilateral/multifocal consolidations (72.2%) were the most common presentations. Lopinavir/ritonavir (usually associated with hydroxychloroquine [HCQ]) was used in 50.0% of patients, and had to be prematurely discontinued in two of them. Other antiviral regimens included HCQ monotherapy (27.8%) and interferon-beta (16.7%). As of April 4, the case fatality rate was 27.8% (5/18). After a median follow-up of 18 days from symptom onset, 30.8% (4/13) of survivors developed progressive respiratory failure, 7.7% (1/13) showed stable clinical condition or improvement, and 61.5% (8/13) had been discharged home. C reactive protein levels at various points were significantly higher among recipients that experienced unfavorable outcome. In conclusion, this frontline report suggests that SARS-CoV-2 infection has a severe course in SOT recipients.","Am J Transplant","Fernandez-Ruiz, Mario","Andres, Amado","Loinaz, Carmelo","Delgado, Juan F","Lopez-Medrano, Francisco","San Juan, Rafael","Gonzalez, Esther","Polanco, Natalia","Folgueira, Maria Dolores","Lalueza, Antonio","Lumbreras, Carlos","Aguado, Jose Maria","32301155"],"abstract":["The clinical characteristics, management and outcome of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) after solid organ transplantation (SOT) remain unknown. We report our preliminary experience with 18 SOT (kidney [44.4%], liver [33.3%] and heart [22.2%]) recipients diagnosed with COVID-19 by March 23, 2020 at a tertiary-care center at Madrid. Median age at diagnosis was 71.0 +/- 12.8 years, and the median interval since transplantation was 9.3 years. Fever (83.3%) and radiographic abnormalities in form of unilateral or bilateral/multifocal consolidations (72.2%) were the most common presentations. Lopinavir/ritonavir (usually associated with hydroxychloroquine [HCQ]) was used in 50.0% of patients, and had to be prematurely discontinued in two of them. Other antiviral regimens included HCQ monotherapy (27.8%) and interferon-beta (16.7%). As of April 4, the case fatality rate was 27.8% (5/18). After a median follow-up of 18 days from symptom onset, 30.8% (4/13) of survivors developed progressive respiratory failure, 7.7% (1/13) showed stable clinical condition or improvement, and 61.5% (8/13) had been discharged home. C reactive protein levels at various points were significantly higher among recipients that experienced unfavorable outcome. In conclusion, this frontline report suggests that SARS-CoV-2 infection has a severe course in SOT recipients."],"journal":"Am J Transplant","authors":["Fernandez-Ruiz, Mario","Andres, Amado","Loinaz, Carmelo","Delgado, Juan F","Lopez-Medrano, Francisco","San Juan, Rafael","Gonzalez, Esther","Polanco, Natalia","Folgueira, Maria Dolores","Lalueza, Antonio","Lumbreras, Carlos","Aguado, Jose Maria"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32301155","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1111/ajt.15929","keywords":["covid-19","sars-cov-2","coronavirus","outcome","solid organ transplantation","treatment"],"locations":["Madrid","Spain"],"countries":["Spain"],"countries_codes":["ESP|Spain"],"e_drugs":["Hydroxychloroquine","lopinavir-ritonavir drug combination"],"topics":["Treatment"],"weight":1,"_version_":1666138494803640321,"score":335.67706},{"pmid":32330343,"title":"COVID-19 in Solid Organ Transplant Recipients: Initial Report from the US Epicenter.","text":["COVID-19 in Solid Organ Transplant Recipients: Initial Report from the US Epicenter.","Solid organ transplant recipients may be at a high risk for SARS-CoV2 infection and poor associated outcomes. We herein report our initial experience with solid organ transplant recipients with SARS-CoV2 infection at two centers during the first 3 weeks of the outbreak in New York City. Baseline characteristics, clinical presentation, antiviral and immunosuppressive management were compared between patients with mild/moderate and severe disease (defined as ICU admission, intubation or death). 90 patients were analyzed with a median age of 57 years. 46 were kidney recipients, 17 lung, 13 liver, 9 heart and 5 dual-organ transplants. The most common presenting symptoms were fever (70%), cough (59%) and dyspnea (43%). 22 (24%) had mild, 41 (46%) moderate and 27 (30%) severe disease. Among the 68 hospitalized patients, 12% required non-rebreather and 35% required intubation. 91% received hydroxychloroquine, 66% azithromycin, 3% remdesivir, 21% tocilizumab and 24% bolus steroids. Sixteen patients died (18% overall, 24% of hospitalized, 52% of ICU) and 37 (54%) were discharged. In this initial cohort, transplant recipients with COVID-19 appear to have more severe outcomes, although testing limitations likely led to undercounting of mild/asymptomatic cases. As this outbreak unfolds, COVID-19 has the potential to severely impact solid organ transplant recipients.","Am J Transplant","Pereira, Marcus R","Mohan, Sumit","Cohen, David J","Husain, S Ali","Dube, Geoffrey K","Ratner, Lloyd E","Arcasoy, Selim","Aversa, Meghan M","Benvenuto, Luke J","Dadhani, Darshana","Kapur, Sandip","Dove, Lorna M","Brown, Robert S","Rosenblatt, Russell E","Samstein, Benjamin","Uriel, Nir","Farr, Maryjane A","Satlin, Michael","Small, Cathy B","Walsh, Thomas","Kodiyanplakkal, Rosy Priya","Miko, Benjamin A","Aaron, Justin G","Tsapepas, Demetra S","Emond, Jean C","Verna, Elizabeth C","32330343"],"abstract":["Solid organ transplant recipients may be at a high risk for SARS-CoV2 infection and poor associated outcomes. We herein report our initial experience with solid organ transplant recipients with SARS-CoV2 infection at two centers during the first 3 weeks of the outbreak in New York City. Baseline characteristics, clinical presentation, antiviral and immunosuppressive management were compared between patients with mild/moderate and severe disease (defined as ICU admission, intubation or death). 90 patients were analyzed with a median age of 57 years. 46 were kidney recipients, 17 lung, 13 liver, 9 heart and 5 dual-organ transplants. The most common presenting symptoms were fever (70%), cough (59%) and dyspnea (43%). 22 (24%) had mild, 41 (46%) moderate and 27 (30%) severe disease. Among the 68 hospitalized patients, 12% required non-rebreather and 35% required intubation. 91% received hydroxychloroquine, 66% azithromycin, 3% remdesivir, 21% tocilizumab and 24% bolus steroids. Sixteen patients died (18% overall, 24% of hospitalized, 52% of ICU) and 37 (54%) were discharged. In this initial cohort, transplant recipients with COVID-19 appear to have more severe outcomes, although testing limitations likely led to undercounting of mild/asymptomatic cases. As this outbreak unfolds, COVID-19 has the potential to severely impact solid organ transplant recipients."],"journal":"Am J Transplant","authors":["Pereira, Marcus R","Mohan, Sumit","Cohen, David J","Husain, S Ali","Dube, Geoffrey K","Ratner, Lloyd E","Arcasoy, Selim","Aversa, Meghan M","Benvenuto, Luke J","Dadhani, Darshana","Kapur, Sandip","Dove, Lorna M","Brown, Robert S","Rosenblatt, Russell E","Samstein, Benjamin","Uriel, Nir","Farr, Maryjane A","Satlin, Michael","Small, Cathy B","Walsh, Thomas","Kodiyanplakkal, Rosy Priya","Miko, Benjamin A","Aaron, Justin G","Tsapepas, Demetra S","Emond, Jean C","Verna, Elizabeth C"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32330343","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1111/ajt.15941","locations":["New York"],"countries":["United States"],"countries_codes":["USA|United States"],"e_drugs":["Hydroxychloroquine","remdesivir","Azithromycin","tocilizumab","Steroids"],"topics":["Treatment"],"weight":1,"_version_":1666138494683054081,"score":316.06815},{"pmid":32402056,"title":"Characteristics and Outcomes of Recipients of Heart Transplant With Coronavirus Disease 2019.","text":["Characteristics and Outcomes of Recipients of Heart Transplant With Coronavirus Disease 2019.","Importance: Recipients of heart transplant (HT) may be at increased risk of adverse outcomes attributable to infection with coronavirus disease 2019 (COVID-19) because of multiple comorbidities and clinically significant immunosuppression. Objective: To describe the characteristics, treatment, and outcomes of recipients of HT with COVID-19. Design, Setting, and Participants: This case series from a single large academic heart transplant program in New York, New York, incorporates data from between March 1, 2020, and April 24, 2020. All recipients of HT followed up by this center who were infected with COVID-19 were included. Interventions: Heart transplant and a confirmed diagnosis of COVID-19. Main Outcomes and Measures: The primary measure was vital status at end of study follow-up. Secondary measures included patient characteristics, laboratory analyses, changes to immunosuppression, and treatment administered for COVID-19. Results: Twenty-eight patients with HT received a confirmed diagnosis of COVID-19. The median age was 64.0 (interquartile range [IQR], 53.5-70.5) years, 22 (79%) were men, and the median time from HT was 8.6 (IQR, 4.2-14.5) years. Comorbid conditions included hypertension in 20 patients (71%), diabetes in 17 patients (61%), and cardiac allograft vasculopathy in 16 patients (57%). Twenty-two participants (79%) were admitted for treatment, and 7 (25%) required mechanical ventilation. Most (13 of 17 [76%]) had evidence of myocardial injury (median high-sensitivity troponin T, 0.055 [IQR, 0.0205-0.1345] ng/mL) and elevated inflammatory biomarkers (median peak high-sensitivity C-reactive protein, 11.83 [IQR, 7.44-19.26] mg/dL; median peak interleukin 6, 105 [IQR, 38-296] pg/mL). Among patients managed at the study institution, mycophenolate mofetil was discontinued in 16 patients (70%), and 6 (26%) had a reduction in the dose of their calcineurin inhibitor. Treatment of COVID-19 included hydroxychloroquine (18 patients [78%]), high-dose corticosteroids (8 patients [47%]), and interleukin 6 receptor antagonists (6 patients [26%]). Overall, 7 patients (25%) died. Among 22 patients (79%) who were admitted, 11 (50%) were discharged home, 4 (18%) remain hospitalized at the end of the study, and 7 (32%) died during hospitalization. Conclusions and Relevance: In this single-center case series, COVID-19 infection was associated with a case fatality rate of 25% in recipients of HT. Immunosuppression was reduced in most of this group of patients. Further study is required to evaluate the optimal approach to management of COVID-19 infection in the HT population.","JAMA Cardiol","Latif, Farhana","Farr, Maryjane A","Clerkin, Kevin J","Habal, Marlena V","Takeda, Koji","Naka, Yoshifumi","Restaino, Susan","Sayer, Gabriel","Uriel, Nir","32402056"],"abstract":["Importance: Recipients of heart transplant (HT) may be at increased risk of adverse outcomes attributable to infection with coronavirus disease 2019 (COVID-19) because of multiple comorbidities and clinically significant immunosuppression. Objective: To describe the characteristics, treatment, and outcomes of recipients of HT with COVID-19. Design, Setting, and Participants: This case series from a single large academic heart transplant program in New York, New York, incorporates data from between March 1, 2020, and April 24, 2020. All recipients of HT followed up by this center who were infected with COVID-19 were included. Interventions: Heart transplant and a confirmed diagnosis of COVID-19. Main Outcomes and Measures: The primary measure was vital status at end of study follow-up. Secondary measures included patient characteristics, laboratory analyses, changes to immunosuppression, and treatment administered for COVID-19. Results: Twenty-eight patients with HT received a confirmed diagnosis of COVID-19. The median age was 64.0 (interquartile range [IQR], 53.5-70.5) years, 22 (79%) were men, and the median time from HT was 8.6 (IQR, 4.2-14.5) years. Comorbid conditions included hypertension in 20 patients (71%), diabetes in 17 patients (61%), and cardiac allograft vasculopathy in 16 patients (57%). Twenty-two participants (79%) were admitted for treatment, and 7 (25%) required mechanical ventilation. Most (13 of 17 [76%]) had evidence of myocardial injury (median high-sensitivity troponin T, 0.055 [IQR, 0.0205-0.1345] ng/mL) and elevated inflammatory biomarkers (median peak high-sensitivity C-reactive protein, 11.83 [IQR, 7.44-19.26] mg/dL; median peak interleukin 6, 105 [IQR, 38-296] pg/mL). Among patients managed at the study institution, mycophenolate mofetil was discontinued in 16 patients (70%), and 6 (26%) had a reduction in the dose of their calcineurin inhibitor. Treatment of COVID-19 included hydroxychloroquine (18 patients [78%]), high-dose corticosteroids (8 patients [47%]), and interleukin 6 receptor antagonists (6 patients [26%]). Overall, 7 patients (25%) died. Among 22 patients (79%) who were admitted, 11 (50%) were discharged home, 4 (18%) remain hospitalized at the end of the study, and 7 (32%) died during hospitalization. Conclusions and Relevance: In this single-center case series, COVID-19 infection was associated with a case fatality rate of 25% in recipients of HT. Immunosuppression was reduced in most of this group of patients. Further study is required to evaluate the optimal approach to management of COVID-19 infection in the HT population."],"journal":"JAMA Cardiol","authors":["Latif, Farhana","Farr, Maryjane A","Clerkin, Kevin J","Habal, Marlena V","Takeda, Koji","Naka, Yoshifumi","Restaino, Susan","Sayer, Gabriel","Uriel, Nir"],"date":"2020-05-14T11:00:00Z","year":2020,"_id":"32402056","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1001/jamacardio.2020.2159","locations":["New York","New York","calcineurin","optimal"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1666714494896701441,"score":296.24118},{"pmid":32423908,"title":"Early Outcomes of Outpatient Management of Kidney Transplant Recipients with Coronavirus Disease 2019.","text":["Early Outcomes of Outpatient Management of Kidney Transplant Recipients with Coronavirus Disease 2019.","BACKGROUND AND OBJECTIVES: Outcomes of kidney transplant recipients diagnosed with coronavirus disease 2019 as outpatients have not been described. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We obtained clinical data for 41 consecutive outpatient kidney transplant recipients with known or suspected coronavirus disease 2019. Chi-squared and Wilcoxon rank sum tests were used to compare characteristics of patients who required hospitalization versus those who did not. RESULTS: Of 41 patients, 22 (54%) had confirmed coronavirus disease 2019, and 19 (46%) were suspected cases. Patients most commonly reported fever (80%), cough (56%), and dyspnea (39%). At the end of follow-up, 13 patients (32%) required hospitalization a median of 8 days (range, 1-16) after symptom onset, and 23 (56%) had outpatient symptom resolution a median of 12 days (4-23) after onset. Patients who required hospitalization were more likely to have reported dyspnea (77% versus 21%, P=0.003) and had higher baseline creatinine (median, 2.0 versus 1.3 mg/dl, P=0.02), but there were no other differences between groups. CONCLUSIONS: In an early cohort of outpatient kidney transplant recipients with known or suspected coronavirus disease 2019, many had symptomatic resolution without requiring hospitalization.","Clin J Am Soc Nephrol","Husain, S Ali","Dube, Geoffrey","Morris, Heather","Fernandez, Hilda","Chang, Jae-Hyung","Paget, Kathryn","Sritharan, Sharlinee","Patel, Shefali","Pawliczak, Olga","Boehler, Mia","Tsapepas, Demetra","Crew, R John","Cohen, David J","Mohan, Sumit","32423908"],"abstract":["BACKGROUND AND OBJECTIVES: Outcomes of kidney transplant recipients diagnosed with coronavirus disease 2019 as outpatients have not been described. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We obtained clinical data for 41 consecutive outpatient kidney transplant recipients with known or suspected coronavirus disease 2019. Chi-squared and Wilcoxon rank sum tests were used to compare characteristics of patients who required hospitalization versus those who did not. RESULTS: Of 41 patients, 22 (54%) had confirmed coronavirus disease 2019, and 19 (46%) were suspected cases. Patients most commonly reported fever (80%), cough (56%), and dyspnea (39%). At the end of follow-up, 13 patients (32%) required hospitalization a median of 8 days (range, 1-16) after symptom onset, and 23 (56%) had outpatient symptom resolution a median of 12 days (4-23) after onset. Patients who required hospitalization were more likely to have reported dyspnea (77% versus 21%, P=0.003) and had higher baseline creatinine (median, 2.0 versus 1.3 mg/dl, P=0.02), but there were no other differences between groups. CONCLUSIONS: In an early cohort of outpatient kidney transplant recipients with known or suspected coronavirus disease 2019, many had symptomatic resolution without requiring hospitalization."],"journal":"Clin J Am Soc Nephrol","authors":["Husain, S Ali","Dube, Geoffrey","Morris, Heather","Fernandez, Hilda","Chang, Jae-Hyung","Paget, Kathryn","Sritharan, Sharlinee","Patel, Shefali","Pawliczak, Olga","Boehler, Mia","Tsapepas, Demetra","Crew, R John","Cohen, David J","Mohan, Sumit"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32423908","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.2215/CJN.05170420","keywords":["covid-19","cohort studies","dyspnea","nonparametric","outpatients","sars-cov2","statistics","coronavirus","creatinine","hospitalization","kidney transplantation","severe acute respiratory syndrome coronavirus 2"],"e_drugs":["Creatinine"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1667252838008356864,"score":293.6555},{"pmid":32412159,"title":"First experience of SARS-CoV-2 infections in solid organ transplant recipients in the Swiss Transplant Cohort Study.","text":["First experience of SARS-CoV-2 infections in solid organ transplant recipients in the Swiss Transplant Cohort Study.","Immunocompromised patients may be at increased risk for complications of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, comprehensive data of SARS-CoV-2 infection in solid organ transplant (SOT) recipients are still lacking. We performed a multicenter nationwide observational study within the Swiss Transplant Cohort Study (STCS) to describe the epidemiology, clinical presentation, treatment and outcomes of the first microbiologically documented SARS-CoV-2 infection among SOT recipients. Overall, 21 patients were included with a median age of 56 years (10 kidney, 5 liver, 1 pancreas, 1 lung, 1 heart and 3 combined transplantations). The most common presenting symptoms were fever (76%), dry cough (57%), nausea (33%) and diarrhea (33%). Ninety-five percent and 24% of patients required hospital and ICU admission, respectively, and 19% were intubated. After a median of 33 days of follow-up, 16 patients were discharged, 3 were still hospitalized and 2 patients died. These data suggest that clinical manifestations of SARS-CoV-2 infection in middle-aged SOT recipients appear to be similar to the general population without an apparent higher rate of complications. These results need to be confirmed in larger cohorts.","Am J Transplant","Tschopp, J","L'Huillier, A G","Mombelli, M","Mueller, N J","Khanna, N","Garzoni, C","Meloni, D","Papadimitriou-Olivgeris, M","Neofytos, D","Hirsch, H H","Schuurmans, M M","Muller, T","Berney, T","Steiger, J","Pascual, M","Manuel, O","van Delden, C","32412159"],"abstract":["Immunocompromised patients may be at increased risk for complications of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, comprehensive data of SARS-CoV-2 infection in solid organ transplant (SOT) recipients are still lacking. We performed a multicenter nationwide observational study within the Swiss Transplant Cohort Study (STCS) to describe the epidemiology, clinical presentation, treatment and outcomes of the first microbiologically documented SARS-CoV-2 infection among SOT recipients. Overall, 21 patients were included with a median age of 56 years (10 kidney, 5 liver, 1 pancreas, 1 lung, 1 heart and 3 combined transplantations). The most common presenting symptoms were fever (76%), dry cough (57%), nausea (33%) and diarrhea (33%). Ninety-five percent and 24% of patients required hospital and ICU admission, respectively, and 19% were intubated. After a median of 33 days of follow-up, 16 patients were discharged, 3 were still hospitalized and 2 patients died. These data suggest that clinical manifestations of SARS-CoV-2 infection in middle-aged SOT recipients appear to be similar to the general population without an apparent higher rate of complications. These results need to be confirmed in larger cohorts."],"journal":"Am J Transplant","authors":["Tschopp, J","L'Huillier, A G","Mombelli, M","Mueller, N J","Khanna, N","Garzoni, C","Meloni, D","Papadimitriou-Olivgeris, M","Neofytos, D","Hirsch, H H","Schuurmans, M M","Muller, T","Berney, T","Steiger, J","Pascual, M","Manuel, O","van Delden, C"],"date":"2020-05-16T11:00:00Z","year":2020,"_id":"32412159","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1111/ajt.16062","topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666897319106183168,"score":280.97144}]}